ConductScience.org, home
RBBP4: RB binding protein 4, chromatin remodeling factor
API referenceFor AI assistants

Gene · 5928

Papers2,308

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

1 to 20 of 2,308

Download this page as JSON
TitleJournalYearPMIDFound bySource
Distinct NGS mutational landscape and prognostic implications in early-onset colorectal cancer: A dual-cohort analysis of TCGA PanCancer Atlas and MSK-IMPACT 50K.PLoS One202642821536PubTator, text miningPubMed
Tumor-cell PD-L1 expression, mismatch repair status, and survival outcomes in colorectal carcinoma: a retrospective Pakistani cohort study.Front Oncol202642806967PubTator, text miningPubMed
SCRMP-mediated SUMOylation of CSNK2B facilitates DNA damage repair to promote cisplatin resistance in small cell lung cancer.Sci Transl Med202642777084PubTator, text miningPubMed
A Lynch Syndrome Family With Germline MLH1 c.931A>G Showing Preserved Tumor MMR Immunostaining but MSI-H Status: A Case Report.Clin Case Rep202642724513PubTator, text miningPubMed
[Unresectable Gastric Cancer Achieving pCR Via Conversion Surgery after Chemotherapy-Implications for Optimizing Individualized Treatment].Gan To Kagaku Ryoho202642723242PubTator, text miningPubMed
Pathological Complete Response and Conversion Gastrectomy after Nivolumab Plus FOLFOX in an 84-Year-Old Man with MSI-High Gastric Cancer Presenting as a Sister Mary Joseph Nodule: A Case Report.Intern Med202642686572PubTator, text miningPubMed
Multicomplex Integrative Structural Modeling of a Human Histone Deacetylase Interactome.Mol Cell Proteomics202642680104PubTator, text miningPubMed
Multi-Omics-Driven Insights into Cancer Biology and Therapeutic Targeting.AAPS PharmSciTech202642675339PubTator, text miningPubMed
Prevalence of High Tumor Mutational Burden Among Pediatric Patients With Solid Tumors.Pediatr Hematol Oncol202642674063PubTator, text miningPubMed
Integrating perioperative inflammation and pathological invasiveness to predict recurrence after curative colorectal cancer surgery: a multicenter cohort study.Front Oncol202642656393PubTator, text miningPubMed
ELAVL1 and ELAVL4 Are Required for Musashi-Dependent Translational Activation.Biomolecules202642650787PubTator, text miningPubMed
[Personalized systemic treatment of metastatic esophageal cancer].Chirurgie (Heidelb)202642616054PubTator, text miningPubMed
Microsatellite Instability-High Somatic-Type Malignancy Arising From a Primary Retroperitoneal Germ Cell Tumor: A Case Report.IJU Case Rep202642614904PubTator, text miningPubMed
Proteomic Differentiation of Colorectal Cancer From Normal Tissue via Ex Vivo E-Biopsy: A Novel Approach to Molecular Sampling for Diagnostic Precision.Cancer Med202642576270PubTator, text miningPubMed
Coagulation and Inflammatory Responses After Tourniquet Release in Total Knee Arthroplasty: Association with Hemodynamic Instability.J Clin Med202642513301PubTator, text miningPubMed
[Analysis on the incidence and perioperative outcomes of immune-related adverse events in preoperative immunotherapy for colorectal cancer based on multicenter real-world data].Zhonghua Wei Chang Wai Ke Za Zhi202642503979PubTator, text miningPubMed
Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025).Br J Cancer202642498744PubTator, text miningPubMed
Expression Levels of DNMT1, HDAC1, and MT1E Genes as Diagnostic Biomarkers for Breast Cancer Clinicopathological Features: In Vitro and In Silico Analyses.Anal Cell Pathol (Amst)202642478333PubTator, text miningPubMed
Characterizing Gynecological Cancers with the Uncommon dMMR/MSS Phenotype in Lynch Syndrome Patients.J Clin Med202642452441PubTator, text miningPubMed
ELAVL1 and ELAVL4 are required for Musashi-dependent translational activation.bioRxiv202642427619PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Next page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/5928/papers

API referenceFor AI assistants